BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Montazerhodjat V, Weinstock DM, Lo AW. Buying cures versus renting health: Financing health care with consumer loans. Sci Transl Med 2016;8:327ps6. [PMID: 26912902 DOI: 10.1126/scitranslmed.aad6913] [Cited by in Crossref: 22] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
Number Citing Articles
1 Towse A, Mauskopf JA. Affordability of New Technologies: The Next Frontier. Value in Health 2018;21:249-51. [DOI: 10.1016/j.jval.2018.01.011] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
2 Hanna E, Toumi M, Dussart C, Borissov B, Dabbous O, Badora K, Auquier P. Funding breakthrough therapies: A systematic review and recommendation. Health Policy 2018;122:217-29. [DOI: 10.1016/j.healthpol.2017.11.012] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
3 Vreman RA, Broekhoff TF, Leufkens HG, Mantel-Teeuwisse AK, Goettsch WG. Application of Managed Entry Agreements for Innovative Therapies in Different Settings and Combinations: A Feasibility Analysis. Int J Environ Res Public Health 2020;17:E8309. [PMID: 33182732 DOI: 10.3390/ijerph17228309] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Michelsen S, Nachi S, Van Dyck W, Simoens S, Huys I. Barriers and Opportunities for Implementation of Outcome-Based Spread Payments for High-Cost, One-Shot Curative Therapies. Front Pharmacol 2020;11:594446. [PMID: 33363468 DOI: 10.3389/fphar.2020.594446] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
5 Stern AD, Alexander BM, Chandra A. How economics can shape precision medicines. Science 2017;355:1131-3. [PMID: 28302813 DOI: 10.1126/science.aai8707] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 3.4] [Reference Citation Analysis]
6 Hensher M, Tisdell J, Canny B, Zimitat C. Health care and the future of economic growth: exploring alternative perspectives. HEPL 2020;15:419-39. [DOI: 10.1017/s1744133119000276] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.7] [Reference Citation Analysis]
7 Philippidis A. Gene Therapy Briefs. Hum Gene Ther Clin Dev 2017;28:167-74. [PMID: 29243984 DOI: 10.1089/humc.2017.29031.bfs] [Reference Citation Analysis]
8 Schaffer SK, Messner D, Mestre-Ferrandiz J, Tambor E, Towse A. Paying for Cures: Perspectives on Solutions to the "Affordability Issue". Value Health 2018;21:276-9. [PMID: 29566833 DOI: 10.1016/j.jval.2017.12.013] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 4.5] [Reference Citation Analysis]
9 Lomas J, Claxton K, Martin S, Soares M. Resolving the "Cost-Effective but Unaffordable" Paradox: Estimating the Health Opportunity Costs of Nonmarginal Budget Impacts. Value Health 2018;21:266-75. [PMID: 29566832 DOI: 10.1016/j.jval.2017.10.006] [Cited by in Crossref: 36] [Cited by in F6Publishing: 26] [Article Influence: 9.0] [Reference Citation Analysis]
10 Hampson G, Towse A, Pearson SD, Dreitlein WB, Henshall C. Gene therapy: evidence, value and affordability in the US health care system. J Comp Eff Res 2018;7:15-28. [PMID: 29144165 DOI: 10.2217/cer-2017-0068] [Cited by in Crossref: 45] [Cited by in F6Publishing: 38] [Article Influence: 9.0] [Reference Citation Analysis]
11 de Bruijn W, Ibáñez C, Frisk P, Bak Pedersen H, Alkan A, Vella Bonanno P, Brkičić LS, Bucsics A, Dedet G, Eriksen J, Fadare JO, Fürst J, Gallego G, Godói IP, Guerra Júnior AA, Gürsöz H, Jan S, Jones J, Joppi R, Kerman S, Laius O, Madzikwa N, Magnússon E, Maticic M, Markovic-Pekovic V, Massele A, Ogunleye O, O'Leary A, Piessnegger J, Sermet C, Simoens S, Tiroyakgosi C, Truter I, Thyberg M, Tomekova K, Wladysiuk M, Vandoros S, Vural EH, Zara C, Godman B. Introduction and Utilization of High Priced HCV Medicines across Europe; Implications for the Future. Front Pharmacol 2016;7:197. [PMID: 27516740 DOI: 10.3389/fphar.2016.00197] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 3.5] [Reference Citation Analysis]
12 Towse A, Fenwick E. Uncertainty and Cures: Discontinuation, Irreversibility, and Outcomes-Based Payments: What Is Different About a One-Off Treatment? Value Health 2019;22:677-83. [PMID: 31198185 DOI: 10.1016/j.jval.2019.03.013] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 4.3] [Reference Citation Analysis]
13 Hendriks S, Pearson SD. Assessing potential cures: are there distinctive elements of value beyond health gain? J Comp Eff Res 2021. [PMID: 33663230 DOI: 10.2217/cer-2020-0190] [Reference Citation Analysis]
14 Spinner DS, Faulkner EC, Carroll MC, Ringo MC, Joines JW. Regenerative Medicine and Cell Therapy in Orthopedics—Health Policy, Regulatory and Clinical Development, and Market Access. Techniques in Orthopaedics 2019;34:224-43. [DOI: 10.1097/bto.0000000000000413] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
15 Koijen RSJ, Van Nieuwerburgh S. Combining Life and Health Insurance*. The Quarterly Journal of Economics 2020;135:913-58. [DOI: 10.1093/qje/qjz037] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 2.3] [Reference Citation Analysis]
16 Døskeland T, Kvaerner JS. Cancer and Portfolio Choice: Evidence from Norwegian Register Data. Review of Finance 2021. [DOI: 10.1093/rof/rfab022] [Reference Citation Analysis]